M. Kulyk & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Levi Strauss
LEVI
|
+$20.9M |
| 2 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$10.9M |
| 3 |
iShares 0-5 Year TIPS Bond ETF
STIP
|
+$1.19M |
| 4 |
Nike
NKE
|
+$1.06M |
| 5 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$665K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royal Bank of Canada
RY
|
+$928K |
| 2 |
American Tower
AMT
|
+$468K |
| 3 |
Apple
AAPL
|
+$290K |
| 4 |
Gilead Sciences
GILD
|
+$260K |
| 5 |
ASML
ASML
|
+$243K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.74% |
| 2 | Financials | 13.12% |
| 3 | Consumer Discretionary | 11.55% |
| 4 | Healthcare | 10.03% |
| 5 | Consumer Staples | 5.36% |
Similar funds
M. Kulyk & Associates's Q3 2024 Portfolio in Review
As of Q3 2024, M. Kulyk & Associates held 118 positions worth $497M, up 16% from $430M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
M. Kulyk & Associates deployed $34.8M of net new capital in Q3 2024, opening 8 new positions and adding to 41 existing holdings. Its largest new stake was First Citizens BancShares: 114 shares worth $210K.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Royal Bank of Canada, an estimated $928K trimmed.
- M. Kulyk & Associates's largest Q3 2024 buy was First Citizens BancShares: 114 shares worth $210K.
- M. Kulyk & Associates added most to Levi Strauss in Q3 2024, an estimated $20.9M increase.
- M. Kulyk & Associates's biggest Q3 2024 reduction was Royal Bank of Canada, cutting an estimated $928K.
- M. Kulyk & Associates fully exited ASML in Q3 2024, selling an estimated $243K.
- M. Kulyk & Associates's ten largest holdings make up 43% of its $497M portfolio in Q3 2024.
- M. Kulyk & Associates opened 8 new positions and closed 4 in Q3 2024.
- M. Kulyk & Associates's portfolio value rose 16% quarter-over-quarter to $497M.
Based on M. Kulyk & Associates's 13F filing for Q3 2024, filed 7 Nov 2024.